N/A N=65 Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2
ARDS · Mechanical Ventilation Complication · Ventilator-Induced Lung Injury
Primary: Number of Participants Who Survived and Died — 1; 31; 14; 19 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Phase 2 N=20 The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
COVID-19 · Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Primary: Oxygen Index (OI) — -0.91 index
Phase 2 N=235 TD-0903 for ALI Associated With COVID-19
Acute Lung Injury (ALI) Associated With COVID-19 · Lung Inflammation Associated With COVID-19
Primary: Part 2: Number of Respiratory Failure-free Days (RFDs) From Randomization to Day 28 — 21.0; 21.0 days — p=0.6137
Phase 2 N=36 Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
N/A N=139 The Role of Circulating Soluble CD74 in Acute Lung Injury
Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants Receiving Mechanical Ventilation — 51; NA participants
Phase 2 N=53 Nebulised Rt-PA for ARDS Due to COVID-19
COVID
Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)
N/A N=224 Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Prone Positioning · High Flow Nasal Cannula · Acute Respiratory Distress Syndrome
Primary: Treatment Failure (Intubation or Death) — 45; 45 Participants
Phase 2 N=33 Hemodynamics and Extravascular Lung Water in Acute Lung Injury
Acute Lung Injury
Primary: The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water
Phase 2 N=5 The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
Lung Injury, Acute
Primary: Heart Rate Assessments Upto Day 7 (Part B) — 87.4; 97.7; 87.9; 95.3 Beats per minute
Phase 2 N=72 A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COVID · Covid-19 · Coronavirus
Primary: Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 23; 22; 1 Participants
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
Phase 2 N=77 SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…
N/A N=417 The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19
COVID-19
Primary: Mechanical Ventilation — 21 Participants
Phase 4 N=103 The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Pulmonary Fibrosis · Interstitial Lung Disease · Respiratory Disease
Primary: Change in Forced Vital Capacity (FVC) — 147.55; 167.72 mL
N/A N=219 Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study
Respiratory Failure · Mechanical Ventilation · Acute Lung Injury
Primary: To Further Characterize ED Mechanical Ventilation — 500 mL
Phase 2 N=90 A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
Respiratory Distress Syndrome, Adult · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8 — 43; -241 pg/mL — p=0.37
Phase 2 N=200 Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
Phase 4 N=31 Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants
Phase 3 N=43 CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Acute Lung Injury
Primary: All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge — 15; 6 Participants
Phase 2 N=132 A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Respiratory Distress Syndrome, Adult
Primary: Ventilator-free Days During Days 1-28 — 10.8; 10.7 Days
Phase 3 N=104 A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
Acute Respiratory Distress Syndrome
Primary: Time to Clinical Improvement or Hospital Discharge up to Day 28 — NA; 19.0; NA; 22.0 days
Phase 2 N=37 Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Clinically Significant Treatment Emergent Events — 37; 30; 22; 20 Number of patients
Phase 3 N=203 Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Critical COVID-19 With Respiratory Failure · Acute Respiratory Distress Syndrome (ARDS) · Corona Virus Infection
Primary: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) — 72; 33 Participants
N/A N=384 Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19
Covid19
Primary: Hospitalists Who Adopt Lung Ultrasound — 4 Participants
Phase 2 N=400 LIPS-A: Lung Injury Prevention Study With Aspirin
Acute Respiratory Distress Syndrome
Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53
Phase 1 N=12 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Phase 2 N=61 LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
COVID · Severe Acute Respiratory Syndrome · Sars-CoV2
Primary: To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per…
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
N/A N=91 Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants